{
  "source": "PA-Med-Nec-Trulance.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 2128-10\nProgram Prior Authorization/Medical Necessity\nMedication Ibsrela® (tenapanor)*, Trulance® (plecanatide)*\nP&T Approval Date 6/2017, 3/2018, 3/2019, 12/2019, 12/2020, 12/2021, 4/2022, 11/2022,\n11/2023, 7/2024\nEffective Date 10/1/2024\n1. Background:\nIbsrela (tenapanor)* is indicated for treatment of irritable bowel syndrome with constipation\n(IBS-C) in adults. Amitiza® (lubiprostone)* is indicated for the treatment of IBS-C in women 18\nyears of age and older, chronic idiopathic constipation (CIC) in adults, and opioid-induced\nconstipation in adult patients with chronic, non-cancer pain, including patients with chronic pain\nrelated to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage\nescalation. Linzess® (linaclotide) and Trulance® (plecanatide)* are indicated for the treatment of\nCIC and for the treatment of adults with IBS-C; while, Motegrity® is indicated for the treatment\nof CIC in adults. Physicians and patients should periodically assess the need for continued\ntreatment with Ibsrela*,Linzess, Motegrity or Trulance*.\nThis prior authorization program is intended to encourage the use of lower cost alternatives\nbefore providing coverage for Ibsrela*and Trulance*.\n2. Coverage Criteriaa:\nA. Chronic Idiopathic Constipation\n1. Initial Authorization\na. Trulance* will be approved based on both of the following criteria:\n1) Diagnosis of chronic idiopathic constipation\n- AND-\n2) History of failure, contraindication, or intolerance to two of the following\n(document drug and date tried):\na) lubiprostone (generic Amitiza)\nb) Linzess\nc) Motegrity\nAuthorization will be issued for 12 months\n2. Reauthorization\na. Trulance* will be approved based on the following criterion:\n© 2024 UnitedHealthcare Services Inc.\n1\n1) Documentation of positive clinical response to therapy\nAuthorization will be issued for 12 months\nB. Irritable Bowel Syndrome with Constipation\n1. Initi",
    "ion:\n© 2024 UnitedHealthcare Services Inc.\n1\n1) Documentation of positive clinical response to therapy\nAuthorization will be issued for 12 months\nB. Irritable Bowel Syndrome with Constipation\n1. Initial Authorization\na. Ibsrela* will be approved based on both of the following criteria:\n1) Diagnosis of irritable bowel syndrome with constipation\n-AND-\n2) History of failure, contraindication, or intolerance to both of the following\n(document date tried):\na) lubiprostone (generic Amitiza)\nb) Linzess\nAuthorization will be issued for 12 months\nb. Trulance* will be approved based on both of the following criteria:\n1) Diagnosis of irritable bowel syndrome with constipation\n-AND-\n2) History of failure, contraindication, or intolerance to both of the following\n(document date tried):\na) lubiprostone (generic Amitiza)\nb) Linzess\nAuthorization will be issued for 12 months\n2. Reauthorization\na. Ibsrela*or Trulance* will be approved based on the following criterion:\n1) Documentation of positive clinical response to therapy\nAuthorization will be issued for 12 months\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n*Ibsrela, Trulance and Brand Amitiza are typically excluded from coverage\n© 2024 UnitedHealthcare Services Inc.\n2\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n• Notification/Prior Authorization may be in place\n4. References:\n1. Amitiza [package insert]. Lexington, MA: Takeda Pharmaceuticals America, Inc.; November\n2020.\n2. Ibsrela [package insert]. Waltham, MA: Ardelyx; April 2022.\n3. Linzess [package insert]. North C",
    "es:\n1. Amitiza [package insert]. Lexington, MA: Takeda Pharmaceuticals America, Inc.; November\n2020.\n2. Ibsrela [package insert]. Waltham, MA: Ardelyx; April 2022.\n3. Linzess [package insert]. North Chicago, IL: AbbVie, Inc; June 2023\n4. Motegrity [package insert]. Lexington, MA: Takeda Pharmaceuticals America, Inc.; November\n2020\n5. Trulance [package insert]. Bridgewater, NJ: Bausch Health US, LLC; March 2024.\nProgram Prior Authorization/Medical Necessity – Ibsrela (tenapanor), Trulance\n(plecanatide)\nChange Control\nDate Change\n6/2017 New program\n3/2018 Added newly approved indication for irritable bowel syndrome with\nconstipation.\n3/2019 Annual review. Modified documentation language, added statement\nregarding use of automated process and updated references.\n12/2019 Added Ibsrela and Zelnorm to criteria.\n12/2020 Removed Ibsrela since noted as discontinued on FDA website.\nUpdated references.\n12/2021 Annual review. Added a step through Motegrity for Trulance for CIC.\nAdded that Trulance is typically excluded form coverage.\n4/2022 Added criteria for Ibsrela. Updated references.\n11/2022 Zelnorm removed since discontinued from market. Updated references.\n11/2023 Annual review. Removed OTC step requirement and added\nlubiprostone. Updated references.\n7/2024 Review. Added documentation requirement. Updated references.\n© 2024 UnitedHealthcare Services Inc.\n3"
  ]
}